« Back to Directory of Resources

Treatments Under Development

Here you will find a list of current treatments under development:

Limit to treatments in



Page 1 of 612345...Last »

Brand Name:
Generic Name: sotatercept
Code Name: ACE-011
Company: Celgene and Acceleron Pharma
FDA Clinical Phase: 2

Description:

ACE-011 is a human fusion protein from the …

Brand Name: Xgeva (also marketed as Prolia)
Generic Name: denosumab
Code Name: AMG162
Company: Amgen
FDA Clinical Phase: 2 & 3

Description:

Prolia is a human monoclonal …

Brand Name:
Generic Name: ridaforolimus (formerly deforolimus)
Code Name: AP23573
Company: Ariad Pharmaceuticals & Merck
FDA Clinical Phase: 1

Description:

Ridaforolimus, formerly known as deforolimus, is …

Brand Name:
Generic Name:
Code Name: AT9283
Company: Astex
FDA Clinical Phase: 2

Description:

AT9283 is a kinase inhibitor that prevents cell division, thereby stopping …

Brand Name:
Generic Name:
Code Name: BI-505
Company: BioInvent
FDA Clinical Phase: 1

Description:

BI-505 is a fully human antibody that causes cell death. It …

Brand Name:
Generic Name:
Code Name: BT-062
Company: Biotest
FDA Clinical Phase: 1/2

Description:

BT-062 (news articles) …

Page 1 of 612345...Last »